Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of pelcitoclax alone or with chidamide in relapsed or refractory non-Hodgkin lymphoma
CTR20213387Phase 2Active
- Sponsor
- Suzhou Yasheng Pharmaceutical
- Start
- Jun 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pelcitoclax, tucidinostat in non-Hodgkin lymphoma (NHL), peripheral T-cell lymphoma (PTCL), sponsored by Suzhou Yasheng Pharmaceutical. Started Jun 2022; status: active.
02
Drugs
pelcitoclaxtucidinostat
03
Conditions
non-Hodgkin lymphoma (NHL)peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on CTR20213387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213387.